JPMorgan Chase & Co. Cuts Inspire Medical Systems (NYSE:INSP) Price Target to $54.00

Key Points

• JPMorgan lowered its price target on Inspire Medical Systems from $67 to $54 and kept a "neutral" rating, joining several brokers that have trimmed targets and shifted to neutral/hold stances.
• The company beat Q1 estimates with $0.10 EPS and $204.6M revenue, but issued a materially lower FY2026 guidance of $0.75–$1.25 EPS and $825M–$875M revenue, citing coding/reimbursement timing and WISeR program disruptions.
• Shares fell sharply (trading to $48.24 on the reported day) amid the guidance cut and analyst downgrades; consensus remains a "Hold" with mixed analyst opinions (four Buys, fifteen Holds, one Sell).

Inspire Medical Systems (NYSE:INSP - Get Free Report) had its target price lowered by stock analysts at JPMorgan Chase & Co. from $67.00 to $54.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s target price would indicate a potential upside of 11.94% from the stock's previous close.

Several other brokerages have also recently weighed in on INSP. Piper Sandler cut Inspire Medical Systems from an "overweight" rating to a "neutral" rating and decreased their price target for the company from $85.00 to $55.00 in a research note on Tuesday. Zacks Research lowered Inspire Medical Systems from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 14th. Royal Bank Of Canada cut their price target on Inspire Medical Systems from $56.00 to $45.00 and set a "sector perform" rating on the stock in a report on Tuesday. Morgan Stanley set a $60.00 target price on Inspire Medical Systems in a report on Wednesday, February 18th. Finally, Truist Financial cut their price target on shares of Inspire Medical Systems from $64.00 to $50.00 and set a "hold" rating on the stock in a report on Tuesday. Four analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $85.00.

Inspire Medical Systems Price Performance

INSP traded down $6.60 during trading on Tuesday, hitting $48.24. The stock had a trading volume of 4,487,559 shares, compared to its average volume of 1,214,082. The company has a 50 day moving average price of $56.73 and a 200-day moving average price of $79.64. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of 9.69, a P/E/G ratio of 2.92 and a beta of 0.83. Inspire Medical Systems has a one year low of $44.41 and a one year high of $163.35.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The firm had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. During the same period in the prior year, the company posted $0.10 EPS. The company's revenue was up 1.6% compared to the same quarter last year. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. As a group, sell-side analysts predict that Inspire Medical Systems will post 1.82 EPS for the current fiscal year.

Institutional Trading of Inspire Medical Systems

Hedge funds have recently made changes to their positions in the company. CWM LLC raised its stake in shares of Inspire Medical Systems by 216.1% in the fourth quarter. CWM LLC now owns 354 shares of the company's stock valued at $33,000 after buying an additional 242 shares during the period. Havemeyer Place LP bought a new stake in shares of Inspire Medical Systems in the fourth quarter valued at $39,000. V Square Quantitative Management LLC bought a new stake in shares of Inspire Medical Systems in the fourth quarter valued at $40,000. Manning & Napier Advisors LLC bought a new stake in shares of Inspire Medical Systems in the third quarter valued at $32,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Inspire Medical Systems by 84.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company's stock valued at $42,000 after buying an additional 205 shares during the period. 94.91% of the stock is currently owned by institutional investors.

Inspire Medical Systems News Summary

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS and $204.6M in revenue, topping consensus and showing modest year‑over‑year growth; the company also released its quarter materials and slide deck. Read More.
• Positive Sentiment: Some firms remain constructive — despite cuts to targets, Stifel and Mizuho kept buy/outperform stances (with lower price targets), indicating some analysts still see upside at lower valuations. Read More.
• Neutral Sentiment: Full earnings call transcript and slide deck are available for detail — investors can review management’s explanations on coding, reimbursement timing and WISeR program impacts. Read More.
• Negative Sentiment: Large FY‑2026 guidance cut — management now expects $0.75–$1.25 EPS and $825M–$875M revenue vs. street expectations near $1.99 EPS and ~$961M revenue, a materially lower outlook that drove investor concern. Read More.
• Negative Sentiment: Reimbursement and WISeR program disruptions cited — management said coding/reimbursement timing and WISeR-related execution issues are reducing procedure volumes in 2026, the main operational reason for the weaker guidance. Read More.
• Negative Sentiment: Multiple analyst price‑target cuts and rating shifts — several brokers trimmed targets (Truist, Wells Fargo, Baird) or moved to neutral/hold, increasing selling pressure after the guidance miss. Read More.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.